- innovativeHealth Group's biotechnological platforms screen and combine different ingredients to develop novel dermocosmetic products using artificial intelligence
- Latest acquisition increases Evonik’s ability to develop unique and tailor-made active ingredients and accelerates time to market
The acquisition of innoHealth further strengthens Evonik’s Health & Care growth engine and allows Evonik to expand its product development for unique active ingredients. This latest move forms part of Evonik’s strategy to target growth for its innovation footprint within, and beyond, the personal care field.
“Evonik’s DNA for development is to innovate new products that show proven efficacy and support unique cosmetic claims,” said Tammo Boinowitz, Senior Vice President and General Manager at Evonik’s Care Solutions Business Line. “In order to screen the right products, we wanted to enlarge our lab capabilities and enhance our screening abilities. This is a core strength of innoHealth – to select the right products that show efficacy.”
In addition to the screening platform, innoHealth developed a tool to combine active ingredients showing synergistic effects. The platform can be used for Evonik’s product development and as a selection tool for its customers. Additionally, Evonik will offer customized active ingredients that meet the specific market trends and consumer needs.
innoHealth’s Ingredient Combinatorial System platform is used to identify synergistic activities between individual ingredients to develop novel dermocosmetic products that offer superior activity for specific applications. The artificial intelligence system implements an algorithm capable of calculating optimized ingredient blends for different applications.
Tammo Boinowitz added: “With this latest acquisition we have strengthened our innovative power in the area of cosmetic active ingredients. We will now be able to optimize the costs and development time, as well as achieve high quality and high performance products that show attractive and scientifically proven properties.”
Prof. Dr. Eduardo Muñoz MD, PhD, Professor of Immunology at the University of Cordoba, and co-founder of innoHealth, said: “innoHealth was created with the mission of offering novel skin care products and to provide technological support for their development. Our major focus has been on a scientific-based approach to new and more effective therapeutic solutions to dermatological skin conditions. Now as part of Evonik we are in a much better position to realize these goals, and we are looking forward to helping Evonik meet its wider targets and goals.”
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.